在本研究中，团队开发了一种称为肿瘤靶向KRAS降解剂（TKD）的新型分子工具，可有效靶向多种KRAS突变体。2024年6月28日，中山大学肿瘤防治中心曾木圣团队在《Cell Discovery》杂志发表了题为"A pan-KRAS degrader for the treatment of KRAS-mutant cancers"的研究论文。本研究的数据表明，TKD选择性地与癌细胞中的KR...
1. Janne, P. A., & van den Heuvel, M. M. (2019). Targeting KRAS Mutant Cancers into the Next Decade. Clinical cancer research, 25(9), 2698-2702. 2. Hegde, M., & Ferreira, M. (2021). Clinical and Molecular Characterization of K...
1. Theclinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. https://doi.org/10.1038/s41586-019-1694-1 2. TheKRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibilityof KRAS Mutant Cancers ...
中国科学院上海药物研究所谭敏佳研究员课题组和黄敏研究员课题组及其合作者在Molecular Cell在线发表题为“A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies”的研究论文，对癌基因KRAS突变肿瘤进行了分子分型，并提出了相应的治疗用药思路。KRAS是人类恶性肿瘤中突变率最高...
C.J. SCHULZE, K. J. SEAMON, Y. ZHAO, et al. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS [J]. Science, 2023, 381(6659): 794-799. M. H. HOFMANN, D. GERLACH, S. MISALE, et al. Expanding the Reach of Precision Oncology by Drugging All...
[3] RMC-9805 (RM-036), a First-in-Class, Orally-Bioavailable, Tri- Complex Covalent KRASG12D(ON) Inhibitor, Drives Profound Anti- Tumor Activity in KRASG12D Mutant Tumor Models. Retrieved April 21, 2022, from https://s3.us-west-2.amazonaws.com/rvmdpubs.revmed.com/2022/AACR_2022_...
2. Chunxiao Zhu , Xiaoqing Guan , Xinuo Zhang, Xin Luan, Zhengbo Song, Xiangdong Cheng, Weidong Zhang, Jiang-Jiang Qin, Targeting KRAS mutant cancers: from druggable therapy to drug resistance, Mol Cancer 2022 Aug 4;21(1):159.
2023 年 8 月 17 日，来自美国纪念斯隆-凯特琳癌症中心 ( MSKCC ) 的研究团队在国际顶级期刊 Science 发文， Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS ，受到分子胶作用机制的启发，基于天然产物开发了一种通过与亲环蛋白 CYPA 形成三元复合物选择性地靶向 KRAS G...
Pratt, Wayne Blosser, Michele Dowless, Nicholas Simpson, Xiu-Juan Yuan, Susan Jaken, Jason Manro, Jennifer Stephens, Youyan Zhang, Lysiane Huber, Sheng-Bin Peng, and Louis F. Stancato. 2017. “LY3009120, a PanRAF Inhibitor, Has Significant Anti-Tumor Activity in BRAF and KRAS Mutant ...
满足上面的基本条件，可联系癌度报名，参加这款新药的临床试验。一旦筛选入组患者的检查和药物费用全免。欢迎大家关注癌度，了解最新的肿瘤诊疗信息！参考文献：Rafael Rosell, et al., KRAS G12C-mutant driven non-small cell lung cancer (NSCLC), Critical Reviews in Oncology / Hematology, (2023).